NANS 2026: Abbott's Vision for Neuromodulation

 

Ryan Lakin, Abbott’s vice president, Neuromodulation, discusses his vision for Abbott Neuromodulation, trends in the market and the top news for the company at the recent North American Neuromodulation Society (NANS) 2026 Annual Meeting in Las Vegas, Nevada in an interview with SmartTRAK.

To listen to the interview, click on the following video (24:08 min). A link to download a complete transcript of the interview is provided below. 

SmartTRAK: Anne Staylor here with SmartTRAK. Today, I'm at the 2026 North American Neuromodulation Society annual meeting in Las Vegas. And I'm talking with Ryan Lakin, Abbott's vice president of Neuromodulation. Hi, Ryan. It's so nice seeing you again.

Ryan Lakin: It's great seeing you too, Anne. Thank you so much for making time today.

And you too. I look back and the last time I interviewed you was in 2022, so it's been a while. And since then, your role has changed quite a bit at Abbott. You were named VP of Neuromodulation just in October ...

And over the years, you've played a big role in Abbott's digital health and product development. So I think you have a unique perspective regarding digital health and where things are going in neuromodulation. So I just want to talk to you a little bit about the trends in neuromodulation right now. But before we dive into that, tell me, from your perspective, what was the big news for Abbott here at NANS?

RL: Well, first, I think Abbott continues to be the leader in neuromodulation. I think that really means, at the end of the day, we're touching a lot of patients. And I think the exciting part, as we ended last year, is we hit a good milestone, which is our products were used in over half a million patients last year, which is just amazing when you see the benefits of the therapies we offer. So you take that and start to look at what does that mean for what we're seeing at NANS this year. The exciting part is, we've taken a lot of data, and you're starting to see real-world evidence around our leadership position. And what we've seen from the performance of our products and presenting five-year outcome data from real-world evidence studies across both our SCS and our DRG therapies is that we are really seeing ...

Click the button below to download the full transcript of the interview "NANS 2026: Abbott's Vision for Neuromodulation."  In this conversation, Ryan Lakin, VP of Abbott, discusses his vision for neuromodulation and trends in the market with Anne Staylor, SmartTRAK Executive Editor, VP & GM of Neuro Therapies.

SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.